Edition:
United Kingdom

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

88.65USD
21 Feb 2019
Change (% chg)

-- (--)
Prev Close
$88.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,823,765
52-wk High
$96.95
52-wk Low
$58.61

Chart for

About

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)

Overall

Beta: 1.88
Market Cap(Mil.): $108,911.00
Shares Outstanding(Mil.): 782.35
Dividend: --
Yield (%): --

Financials

  CELG.OQ Industry Sector
P/E (TTM): 43.29 30.48 33.70
EPS (TTM): 3.22 -- --
ROI: 10.08 14.95 14.45
ROE: 37.19 16.27 15.96

Bristol-Myers says Starboard nominated five directors, bought shares

Bristol-Myers Squibb Co said on Wednesday that activist hedge fund Starboard Value LP intends to nominate five directors to the U.S. drugmaker's board, one month after it announced a $74 billion deal to acquire peer Celgene Corp.

20 Feb 2019

UPDATE 1-Bristol-Myers says Starboard nominated five directors, bought shares

Feb 20 Bristol-Myers Squibb Co said on Wednesday that activist hedge fund Starboard Value LP intends to nominate five directors to the U.S. drugmaker's board, one month after it announced a $74 billion deal to acquire peer Celgene Corp.

20 Feb 2019

Bristol-Myers says Starboard nominated five directors, bought shares

BOSTON, Feb 20 Bristol-Myers Squibb Co. said on Wednesday that activist hedge fund Starboard Value LP wants to add five directors to its board and bought one million shares after the pharmaceutical company said it plans to buy biotech company Celgene Corp.

20 Feb 2019

Starboard gauges Bristol-Myers shareholder support for Celgene deal

Activist hedge fund Starboard Value LP has asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co shareholders for the U.S. drug maker's $74 billion deal to buy Celgene Corp, people familiar with the matter said on Friday.

16 Feb 2019

Starboard gauges Bristol-Myers shareholder support for Celgene deal

Activist hedge fund Starboard Value LP has asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co shareholders for the U.S. drug maker's $74 billion (57 billion pounds) deal to buy Celgene Corp, people familiar with the matter said on Friday.

16 Feb 2019

Starboard gauges Bristol-Myers shareholder support for Celgene deal

Feb 15 Activist hedge fund Starboard Value LP has asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co shareholders for the U.S. drug maker's $74 billion deal to buy Celgene Corp, people familiar with the matter said on Friday.

16 Feb 2019

Celgene profit beats as psoriasis drug sales surge

Celgene Corp, which is being bought by Bristol-Myers Squibb Co, reported a better-than-expected fourth-quarter profit on Thursday, driven mainly by higher sales of psoriasis drug Otezla.

31 Jan 2019

UPDATE 1-Celgene profit beats as psoriasis drug sales surge

Jan 31 Celgene Corp, which is being bought by Bristol-Myers Squibb Co, reported a better-than-expected fourth-quarter profit on Thursday, driven mainly by higher sales of psoriasis drug Otezla.

31 Jan 2019

Celgene posts 16 pct rise in fourth quarter revenue

Jan 31 Celgene Corp, which is being bought by Bristol-Myers Squibb Co, reported a nearly 16 percent rise in fourth-quarter revenue on Thursday, driven by higher sales of its blockbuster cancer drug Revlimid and psoriasis treatment Otezla.

31 Jan 2019

AbbVie not contemplating big deals - CEO

Jan 25 AbbVie Inc is not considering a big merger or an acquisition, Chief Executive Officer Richard Gonzalez said on Friday, allaying speculations of the company launching a bid for Bristol-Myers Squibb.

25 Jan 2019

Earnings vs. Estimates